OBJECTIVES: I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.

Condition	Treatment or Intervention	Phase
Systemic Lupus Erythematosus	Procedure: ultraviolet A-1 light treatment	Phase II

Further Study Details: 

Expected Total Enrollment:  20

PROTOCOL OUTLINE: Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.

Ages Eligible for Study:  15 Years   -   70 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls

--Prior/Concurrent Therapy--

No requirement for tetracycline or other photosensitizing drugs

Louisiana
      Alton Ochsner Medical Foundation Hospital, New Orleans,  Louisiana,  70121,  United States; Recruiting
      General Clinical Research Center and Charity Hospital (University of Louisiana), New Orleans,  Louisiana,  70112-2822,  United States; Recruiting

Study chairs or principal investigators

Hugh McGrath, Jr.,  Study Chair,  Louisiana State University   

Study ID Numbers:  NCRR-M01RR05096-0002; LSUMC-1765; LSUMC-910067
Record last reviewed:  January 2004
Last Updated:  March 25, 2005
Record first received:  October 18, 1999
ClinicalTrials.gov Identifier:  NCT00004375
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08